BeOne Medicines (NASDAQ:ONC) SVP Sells $103,159.04 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 332 shares of BeOne Medicines stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $310.72, for a total value of $103,159.04. Following the completion of the transaction, the senior vice president directly owned 101 shares of the company’s stock, valued at approximately $31,382.72. This represents a 76.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total value of $103,447.88.
• On Wednesday, March 11th, Chan Henry Lee sold 341 shares of BeOne Medicines stock. The stock was sold at an average price of $300.00, for a total value of $102,300.00.

BeOne Medicines Stock Performance

NASDAQ ONC traded down $11.35 during trading hours on Friday, hitting $293.27. The company’s stock had a trading volume of 269,684 shares, compared to its average volume of 254,986. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $227.05 and a 12 month high of $385.22. The company’s 50 day simple moving average is $300.53 and its two-hundred day simple moving average is $321.93. The company has a market cap of $32.18 billion, a P/E ratio of 65.61 and a beta of 0.50. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion during the quarter. As a group, sell-side analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.3 EPS for the current fiscal year.

Institutional Investors Weigh In On BeOne Medicines

A number of large investors have recently made changes to their positions in ONC. Bank of America Corp DE bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $67,657,000. Man Group plc bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $59,031,000. Capital International Investors grew its stake in shares of BeOne Medicines by 3.3% during the 3rd quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock valued at $1,716,883,000 after purchasing an additional 161,052 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $38,337,000. Finally, First Trust Advisors LP lifted its position in shares of BeOne Medicines by 91.9% during the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after buying an additional 115,601 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Royal Bank Of Canada lifted their price objective on BeOne Medicines from $423.00 to $425.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Leerink Partners lifted their price objective on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a report on Friday. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Wells Fargo & Company assumed coverage on BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective for the company. Finally, Barclays lifted their price objective on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $389.15.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.